DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Young, Empowered & Strong (YES): The Young Women's Breast Cancer Study 2- Focus on Intervention Pilot

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Other: YES portal

First Posted Date: 2019-04-12

Last Posted Date: 2025-04-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT03913936

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Myeloproliferative Neoplasms
Chronic Myelomonocytic Leukemia
Myelofibrosis
Myelodysplastic Syndromes

Interventions: Drug: Ipilimumab
Biological: CD25hi Treg depleted DLI

First Posted Date: 2019-04-11

Last Posted Date: 2024-07-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT03912064

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for Pain

Completed

Conditions: Cancer

Interventions: Behavioral: Acceptance & Commitment Therapy

First Posted Date: 2019-04-10

Last Posted Date: 2022-05-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT03910296

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

Phase 2

Active, not recruiting

Conditions: Liposarcoma
Undifferentiated Pleomorphic Sarcoma
Sarcoma
Leiomyosarcoma

Interventions: Drug: Eribulin
Drug: Pembrolizumab

First Posted Date: 2019-04-02

Last Posted Date: 2025-05-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 57

Registration Number: NCT03899805

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Nivolumab
Drug: Cisplatin
Drug: Docetaxel
Radiation: Intensity-modulated radiotherapy

First Posted Date: 2019-03-29

Last Posted Date: 2023-12-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 6

Registration Number: NCT03894891

Locations: 🇺🇸
The Tisch Cancer Institute, New York, New York, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States

and more 1 locations

Personal Web Page In Clinical Trial Participant Education

Not Applicable

Completed

Conditions: Prostate Cancer
Kidney Cancer
Genitourinary Cancer

Interventions: Other: Postwire

First Posted Date: 2019-03-22

Last Posted Date: 2019-06-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 99

Registration Number: NCT03887091

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma

Not Applicable

Recruiting

Conditions: Head and Neck Cancer

Interventions: Radiation: Radiation therapy

First Posted Date: 2019-03-15

Last Posted Date: 2025-02-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 111

Registration Number: NCT03875716

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Individualizing Surveillance Mammography for Older Breast Cancer Survivors

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Other: Communication Tool

First Posted Date: 2019-03-07

Last Posted Date: 2022-08-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT03865654

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

EHR-embedded OCDT in Breast or GI Cancer

Not Applicable

Completed

Conditions: Oral Chemotherapy
Breast Cancer
Gastrointestinal Cancer
Oral Cancer Directed Therapy

Interventions: Other: Active Care Team Alert
Other: Passive Care Team Alert

First Posted Date: 2019-03-01

Last Posted Date: 2022-05-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 100

Registration Number: NCT03858712

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

'ADVANCE' (A Pilot Trial)

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Cyclophosphamide
Drug: Carboplatin

First Posted Date: 2019-02-28

Last Posted Date: 2025-02-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 41

Registration Number: NCT03858322

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) at Milford Regional Medical Center, Milford, Massachusetts, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy